A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Àkótán ìròyìn
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Tẹ̀lé ìròyìn tuntun láti ọ̀dọ̀ àwọn olùtẹ̀jáde tó ṣeé gbẹ́kẹ̀lé pẹ̀lú àkótán kúkúrú. Ṣí ìjápọ̀ orísun àtilẹ̀wá fún àlàyé.